TREATMENT WITH I-131 METAIODOBENZYLGUANIDINE IN METASTATIC CARCINOID
TREATMENT WITH I-131 METAIODOBENZYLGUANIDINE IN METASTATIC CARCINOID
批准号:
6243960
负责人:
JON P GOCKERMAN
金额:
$3.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1975
资助国家:
美国
项目状态:
已结题
起止时间:
1975-10-01 至 1998-11-30
中文摘要
先前的研究表明,虽然放松训练可能有
英文摘要
Previous research has suggested that while relaxation training may have
little effect on an unselected sample of patients with non-insulin
dependent diabetes mellitus (NIDDM), it may be effective in improving
glucose tolerance in the subset of individuals who show high Trait
Anxiety. The primary purpose of the proposed investigation is to
determine if a relaxation-based stress management therapy (stress
management) can significantly improve metabolic control in a group of
individuals with NIDDM pre-selected for high Trait Anxiety. We will
examine the acute and chronic effects of stress management on diabetes
control in high and low Trait Anxiety patients with NIDDM, determine the
relationship between changes in perceived anxiety and changes in blood
glucose control in these patients and, in addition, we will perform
exploratory analyses to determine if patients with repressive coping
style (low Trait Anxiety and high social desirability), also show
improvements in glucose metabolism with stress management training.
Methods. We use a 2 X 2 design with a high anxious group and a low
anxious group, half of each group randomly assigned to receive the
intervention of stress management training. The training will be
conducted in 5, small-group classes at weekly intervals during the first
2 months of the study year. All subjects will attend 5 weekly classes--
general diabetes education (for controls) and diabetes education plus
stress management training (for experimentals).
All subjects will be followed for 1 year, with assessments at baseline,
2 months, 4 months, 6 months, 9 months (phone) and 12 months.
Variables include glucose tolerance, glucose stimulated insulin
response, plasma glucagon levels, fasting plasma glucose/insulin,
hemoglobin A1c, fructosamine, perceived anxiety/stress level,
mean/variability of home-monitored blood glucose, diet analysis,
learning [of diabetes education and stress management content], exercise
level. In addition to these, history and physical exam, NEO Personality
Inventory and Marlowe Crown Social Desirability Scale will be
administered at baseline only.
Men and women with NIDDM not requiring insulin treatment, will
participate. Volunteers will first be screened using the STAI. Using
norms for an adult general medical-surgical population published in the
STAI manual (18), potential subjects will be classified into tertiles of
high, low or moderate Trait Anxiety. Persons with scores in the high
Trait Anxiety or low Trait Anxiety tertiles will be asked to complete
the entire study. We estimate 360-400 people will need to complete the
STAI in order to define 120 patients (each) in the upper and lower
tertiles of Trait anxiety.
Volunteers that meet high or low Trait anxiety criteria will give
consent and undergo baseline studies. They will also be given, and
instructed in the use of, a One Touch II blood glucose monitor.
Following baseline studies, subjects will be randomly assigned to
stress management training or control condition, and will be scheduled
to begin their weekly sessions with a small group cohort. Significance.
Relaxation training has been previously shown to have acute effects on
glucose tolerance in NIDDM with greater effects observable in patients
with high Trait Anxiety. This project will determine if a relaxation-
based stress management program can have a clinically meaningful long-
term impact on blood glucose control in high trait-anxious patients. If
such an effect can be demonstrated, then we will be able to pre-select
treatment responsive individuals. In addition, success in applying this
individual difference paradigm to the treatment of diabetes will suggest
that similar approaches with other diseases, such as hypertension,
should be tried. Plans. Over the past year we have screened 200
subjects (identifying those with High and Low trait anxiety) and
attempted to enroll in the intervention phase those subjects scoring
either >51 or <27 on the screening tool. Because of the small numbers
of screened subjects in these score ranges, we have started to enroll
all screened [interested and willing] subjects regardless of anxiety
scores.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT WITH I131 METAIODOBENZYLGUANIDINE IN METASTATIC CARCINOID
-
批准号:6273981
-
项目类别:
-
资助金额:$2.88万
-
财政年份:1997
-
负责人:JON P GOCKERMAN
-
依托单位:
PHASE I--TREATMENT WITH I-131 METAIODOBENZYLGUANIDINE IN METASTATIC CARCINOID
-
批准号:5215612
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JON P GOCKERMAN
-
依托单位:--
TREATMENT WITH I131 METAIODOBENZYLGUANIDINE IN METASTATIC CARCINOID
-
批准号:6112747
-
项目类别:
-
资助金额:$3.99万
-
财政年份:--
-
负责人:JON P GOCKERMAN
-
依托单位:
海外基金